The primary goal of this study was to determine if manipulation of brain-RAS with the AT1 receptor antagonist, losartan, could prevent the DA neuronal loss caused by the parkinsonism-inducing neurotoxin, MPTP. The gene discussed is AGTR1; the disease is Parkinson disease.